Christoph Röllig

Städtisches Klinikum Dresden — Germany

Medicine · Health Sciences

58h-index16.2kcitations516works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(368), Chronic Myeloid Leukemia Treatments(130), Multiple Myeloma Research and Treatments(91), Myeloproliferative Neoplasms: Diagnosis and Treatment(84), Acute Lymphoblastic Leukemia research(75)

Publications513 total

Supplementary Figure 2 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025Open Access
Supplementary Tables 1-7 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025Open Access
Image-based explainable artificial intelligence accurately identifies myelodysplastic neoplasms beyond conventional signs of dysplasia
npj Precision Oncology·2025· 1 citedOpen Access
Supplementary Figure 5 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025Open Access
Supplementary Figure 1 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025Open Access
Supplementary Figure 4 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025Open Access
Supplementary Figure 7 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025Open Access
Supplementary Figure 3 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025Open Access
Supplementary Figure 6 from Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
2025Open Access
Supplementary Tables S1-S4 from A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia
2025Open Access
Supplementary Figures S1-S9 from A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia
2025Open Access
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial
Blood·2025
Generating reliable synthetic clinical trial Data: The role of hyperparameter optimization and domain constraints
Information Sciences·2025Open Access
Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome
Blood·2025Open Access
Venetoclax combined with five days of azacitidine for the treatment of previously untreated Acute Myeloid Leukemia (AML): Initial results of the prospective venaza-5S trial
Blood·2025Open Access
Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group
Blood·2025Open Access
Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data
Blood·2025Open Access
Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials
Blood·2025· 1 citedOpen Access
Acute myeloid leukemias with UBTF tandem duplications respond to combined BCL-2 and RNA polymerase I inhibition with increased stemness and a quiescent-like state
Blood·2025Open Access
Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT
Blood·2025Open Access
page 1 of 26Next →

Frequent Co-authors

Martin Bornhäuser(32), Gerhard Ehninger(32), Christian Thiede(29), Michael Krämer(20), Uwe Platzbecker(18), Friedrich Stölzel(18), Hubert Serve(17), Johannes Schetelig(17), Markus Schaich(15), Wolfgang E. Berdel(13), Claudia D. Baldus(11), Hermann Einsele(10), Kerstin Schäfer‐Eckart(10), Mathias Hänel(10), Andreas Neubauer(9), Carsten Müller‐Tidow(9), Malte von Bonin(9), Brigitte Mohr(9), Jan Moritz Middeke(9), Matthias Stelljes(7)